一品红：全资子公司芩香清解口服液获药物临床试验批准通知书

Core Viewpoint - The company Yipinhong's wholly-owned subsidiary, Yipinhong Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of its drug Qinxiangqing Oral Solution, aimed at treating acute upper respiratory infections in adults [1] Group 1 - The drug Qinxiangqing Oral Solution has been assigned the acceptance number CYZB2502650 for its clinical trial application [1] - The approval notification for the clinical trial is documented under the number 2026LP00262 [1] - The clinical trial will focus on the treatment of adults with acute upper respiratory infections characterized by both heat and cold symptoms [1]